<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Managing the side effects of tamoxifen and aromatase inhibitors</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Managing the side effects of tamoxifen and aromatase inhibitors</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Managing the side effects of tamoxifen and aromatase inhibitors</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Suzanne D Conzen, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">N Lynn Henry, MD, PhD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Daniel F Hayes, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">William F Crowley, Jr, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sadhna R Vora, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Dec 08, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9972" href="/d/drug information/9972.html" rel="external">Tamoxifen</a> and aromatase inhibitors (AIs) play a role in both breast cancer prevention and treatment.</p><p><a class="drug drug_general" data-topicid="9972" href="/d/drug information/9972.html" rel="external">Tamoxifen</a> (as well as <a class="drug drug_general" data-topicid="9593" href="/d/drug information/9593.html" rel="external">raloxifene</a>) has antiestrogenic activity in breast tissue, reducing epithelial cell proliferation [<a href="#rid1">1,2</a>]. However, because tamoxifen and raloxifene modulate estrogen receptor (ER) metabolism in a tissue-specific manner, acting as either ER agonists or antagonists depending on the tissue, they have somewhat different side effect profiles. An important difference between the two drugs is their effect on the uterus, where tamoxifen has an estrogen-like effect while raloxifene acts as an estrogen antagonist. In apparent contrast to raloxifene, tamoxifen has been associated with endometrial hyperplasia [<a href="#rid3">3,4</a>], fibroids, polyps [<a href="#rid4">4-6</a>], and endometrial tumors (estrogen agonist effects) [<a href="#rid7">7,8</a>]. Tamoxifen is also associated with other side effects, including hot flashes (an estrogen antagonist effect), vaginal discharge, menstrual irregularities, sexual dysfunction, and blood clots. Although longer treatment with tamoxifen increases the risk of adverse effects, the reduction in breast cancer mortality associated with longer treatment often outweighs those risks. (See  <a class="medical medical_review" href="/d/html/756.html" rel="external">"Selective estrogen receptor modulators and aromatase inhibitors for breast cancer prevention"</a>.)</p><p><a class="drug drug_general" data-topicid="9593" href="/d/drug information/9593.html" rel="external">Raloxifene</a> and <a class="drug drug_general" data-topicid="9972" href="/d/drug information/9972.html" rel="external">tamoxifen</a> are also metabolized differently in the liver. While tamoxifen is metabolized by the liver cytochrome P450 enzymes, raloxifene is metabolized by glucuronidation, and therefore avoids some of the potential issues with drug interactions that apply to tamoxifen. (See  <a class="medical medical_review" href="/d/html/762.html" rel="external">"Mechanisms of action of selective estrogen receptor modulators and down-regulators", section on 'Patients taking SSRIs'</a>.)</p><p>The AIs (<a class="drug drug_general" data-topicid="10064" href="/d/drug information/10064.html" rel="external">letrozole</a>, <a class="drug drug_general" data-topicid="8780" href="/d/drug information/8780.html" rel="external">anastrozole</a>, and <a class="drug drug_general" data-topicid="8920" href="/d/drug information/8920.html" rel="external">exemestane</a>) do not have tissue-specific effects because they suppress plasma estrogen levels globally, by inhibition of the enzyme aromatase. Aromatase is responsible for the peripheral conversion of androgens to estrogens. AIs are associated with loss of bone density, musculoskeletal pains and stiffness, and sexual dysfunction, among other side effects.</p><p>This topic review will cover management of the major side effects of <a class="drug drug_general" data-topicid="9972" href="/d/drug information/9972.html" rel="external">tamoxifen</a> and AIs. The use of these agents as hormonal treatment for breast cancer, both in the adjuvant setting and for advanced disease, and their use as chemopreventive agents in women at increased risk for breast cancer are discussed elsewhere. <a class="drug drug_general" data-topicid="9593" href="/d/drug information/9593.html" rel="external">Raloxifene</a> as a chemopreventive agent is also discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/749.html" rel="external">"Adjuvant endocrine and targeted therapy for postmenopausal women with hormone receptor-positive breast cancer"</a> and  <a class="medical medical_review" href="/d/html/756.html" rel="external">"Selective estrogen receptor modulators and aromatase inhibitors for breast cancer prevention"</a>.)</p><p class="headingAnchor" id="H1535854332"><span class="h1">SIDE EFFECTS COMMON BOTH WITH TAMOXIFEN AND AIS</span></p><p class="headingAnchor" id="H3"><span class="h2">Hot flashes</span><span class="headingEndMark"> — </span>Hot flashes are one of the most common and bothersome side effects both with <a class="drug drug_general" data-topicid="9972" href="/d/drug information/9972.html" rel="external">tamoxifen</a> and AIs; they are believed to be due to a central nervous system antiestrogenic effect causing thermoregulatory dysfunction [<a href="#rid9">9</a>]. Treatment typically includes nonhormonal strategies, including lifestyle modifications, selective serotonin or serotonin-norepinephrine reuptake inhibitors (SSRIs/SNRIs), or gabapentinoids, which are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/7390.html" rel="external">"Menopausal hot flashes", section on 'Women with breast cancer'</a>.)</p><p>Some risk factors for endocrine therapy-induced hot flashes have been identified:</p><p class="bulletIndent1"><span class="glyph">●</span>Premenopausal women have a greater increase in hot flashes after starting <a class="drug drug_general" data-topicid="9972" href="/d/drug information/9972.html" rel="external">tamoxifen</a> compared with perimenopausal or postmenopausal women [<a href="#rid10">10-13</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Polymorphisms in drug-metabolizing enzymes (cytochrome P450 enzyme, CYP2D6) decrease the conversion of <a class="drug drug_general" data-topicid="9972" href="/d/drug information/9972.html" rel="external">tamoxifen</a> to its most active metabolite (endoxifen), and they may influence the likelihood of tamoxifen-related hot flashes, although the available data are conflicting [<a href="#rid14">14,15</a>]. (See  <a class="medical medical_review" href="/d/html/762.html" rel="external">"Mechanisms of action of selective estrogen receptor modulators and down-regulators", section on 'Tamoxifen resistance in breast cancer'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Likewise, coadministration of drugs that inhibit the activity of CYP2D6, such as the SSRIs, reduce endocrine therapy-related hot flashes. However, strong CYP2D6 inhibitors have the potential to adversely affect <a class="drug drug_general" data-topicid="9972" href="/d/drug information/9972.html" rel="external">tamoxifen</a> efficacy, in particular. Among SSRIs, there is a gradient of potency for inhibition of CYP2D6; for example, <a class="drug drug_general" data-topicid="9743" href="/d/drug information/9743.html" rel="external">paroxetine</a> and <a class="drug drug_general" data-topicid="8465" href="/d/drug information/8465.html" rel="external">fluoxetine</a> are strong CYP2D6 inhibitors, while <a class="drug drug_general" data-topicid="9886" href="/d/drug information/9886.html" rel="external">sertraline</a> and <a class="drug drug_general" data-topicid="8484" href="/d/drug information/8484.html" rel="external">duloxetine</a> are moderate inhibitors. However, the data to suggest that this issue decreases tamoxifen effect are very weak, at best. Therefore, the choice of which SSRI or SNRI is up to the individual clinician based on the agent's effectiveness in patient symptoms and their comfort with a specific agent. (See  <a class="medical medical_review" href="/d/html/762.html" rel="external">"Mechanisms of action of selective estrogen receptor modulators and down-regulators", section on 'Tamoxifen resistance in breast cancer'</a> and  <a class="medical medical_review" href="/d/html/7390.html" rel="external">"Menopausal hot flashes", section on 'Women with breast cancer'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Inheritance of specific estrogen receptor and aromatase genotypes may also influence the risk and severity of endocrine therapy-induced hot flashes, although the findings have not yet been validated in independent cohorts [<a href="#rid11">11,16</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hot flashes and night sweats occur with both <a class="drug drug_general" data-topicid="9972" href="/d/drug information/9972.html" rel="external">tamoxifen</a> and the AIs. However, studies suggest that for many women treated with AIs, vasomotor symptoms are less clinically bothersome [<a href="#rid17">17-19</a>].</p><p></p><p>While evaluation of genetic risk factors for tamoxifen-induced hot flashes such as these might hold promise for future selection of candidates for alternative therapeutic strategies when <a class="drug drug_general" data-topicid="9972" href="/d/drug information/9972.html" rel="external">tamoxifen</a> is indicated, genetic testing is not yet ready for clinical use.</p><p class="headingAnchor" id="H3273569704"><span class="h2">Sexual dysfunction</span><span class="headingEndMark"> — </span>Women on <a class="drug drug_general" data-topicid="9972" href="/d/drug information/9972.html" rel="external">tamoxifen</a> or AIs are at an increased risk for vaginal symptoms, including vaginal discharge and dryness, and sexual dysfunction. Women should be counseled about these potential adverse effects as part of their education before starting treatment and on methods that may help alleviate them. The approach to breast cancer survivors who complain of sexual dysfunction is covered separately. (See  <a class="medical medical_review" href="/d/html/5443.html" rel="external">"Genitourinary syndrome of menopause (vulvovaginal atrophy): Treatment", section on 'Patients with breast cancer'</a> and  <a class="medical medical_review" href="/d/html/5443.html" rel="external">"Genitourinary syndrome of menopause (vulvovaginal atrophy): Treatment", section on 'Initial therapy with moisturizers and lubricants'</a> and  <a class="medical medical_review" href="/d/html/754.html" rel="external">"Overview of long-term complications of therapy in breast cancer survivors and patterns of relapse", section on 'Menopausal symptoms'</a>.)</p><p class="headingAnchor" id="H822244178"><span class="h3">Special considerations for premenopausal women receiving OFS</span><span class="headingEndMark"> — </span>In the TEXT and SOFT trials, patients assigned <a class="drug drug_general" data-topicid="8920" href="/d/drug information/8920.html" rel="external">exemestane</a> plus ovarian function suppression (OFS) reported greater bone or joint pain, vaginal dryness, loss of sexual interest, and difficulties becoming aroused than patients on <a class="drug drug_general" data-topicid="9972" href="/d/drug information/9972.html" rel="external">tamoxifen</a> plus OFS; by contrast, patients assigned tamoxifen plus OFS were more affected by hot flashes and sweats than those on exemestane plus OFS [<a href="#rid20">20</a>].</p><p>In SOFT and TEXT, 24 percent of patients on <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.sciencedirect.com%2Ftopics%2Fmedicine-and-dentistry%2Fexemestane&amp;token=%2FHOSBc8zqgGsL8Kgyi8yldPQih7V%2B%2BNOO%2Bt0poLKhhgPYoMVJHYW%2BmfPFhv0NZ%2Fi9GdO0LrjisHSr2o%2BZDtwh8TqBT0Zyi%2BqpjcYoKRz79M%3D&amp;TOPIC_ID=764" target="_blank">exemestane</a> plus OFS and 19 percent on <a class="drug drug_general" data-topicid="9972" href="/d/drug information/9972.html" rel="external">tamoxifen</a> plus OFS stopped protocol-specified treatment early [<a href="#rid21">21</a>], suggesting that approximately one-quarter of patients will have substantial endocrine symptoms.</p><p class="headingAnchor" id="H952911756"><span class="h2">Other side effects</span><span class="headingEndMark"> — </span>Patients treated with endocrine therapy report a variety of symptoms. In one study, women on AIs and <a class="drug drug_general" data-topicid="9972" href="/d/drug information/9972.html" rel="external">tamoxifen</a> [<a href="#rid22">22</a>] reported higher rates of cognitive problems compared with women with breast cancer who did not take endocrine therapy; also, physical health scores one year after initiation of treatment were worse [<a href="#rid23">23</a>]. In another study, predictors of drug discontinuation at one year included fatigue, forgetfulness, and poor sleep hygiene [<a href="#rid24">24</a>]. Finally, both AIs and tamoxifen have also been associated with hair thinning, which is improved with topical <a class="drug drug_general" data-topicid="9655" href="/d/drug information/9655.html" rel="external">minoxidil</a> in the majority of cases [<a href="#rid25">25</a>].</p><p class="headingAnchor" id="H4030191604"><span class="h1">TAMOXIFEN</span></p><p class="headingAnchor" id="H4"><span class="h2">Venous thromboembolism</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Increased risks for venous thromboembolism</strong> <strong>(VTE)</strong> – A number of studies have demonstrated that <a class="drug drug_general" data-topicid="9972" href="/d/drug information/9972.html" rel="external">tamoxifen</a> use is associated with an increased rate of <strong>venous</strong> thromboembolic events [<a href="#rid26">26-28</a>]. The relative risks (RRs) of VTE are increased two- to threefold in women receiving tamoxifen compared with those not taking tamoxifen. Additionally, while some elevated risk of thromboembolic events associated with tamoxifen appears to continue as long as the patient takes the drug, the RR decreases with time after initiation of therapy, with the first two years being the most hazardous [<a href="#rid29">29</a>].</p><p></p><p class="bulletIndent1">Nevertheless, more women experience pulmonary embolism (PE) when the treatment course of <a class="drug drug_general" data-topicid="9972" href="/d/drug information/9972.html" rel="external">tamoxifen</a> is extended to 10 years from 5 years (hazard ratio 1.87, 95% CI 1.13-3.07) [<a href="#rid30">30</a>].</p><p></p><p>Risk factors for tamoxifen-induced VTE include prior surgery, fracture, obesity, and immobilization. Atherosclerotic risk factors, including older age, elevated blood pressure, high total cholesterol, smoking, and a family history of coronary heart disease (CHD), also have been shown to increase the risk of VTE among <a class="drug drug_general" data-topicid="9972" href="/d/drug information/9972.html" rel="external">tamoxifen</a> users [<a href="#rid31">31</a>]. In addition, there is evidence that patients receiving tamoxifen who harbor a heterozygous Factor V Leiden mutation have a nearly fivefold risk of thromboembolism relative to those taking tamoxifen who do not have a mutation [<a href="#rid32">32</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Decreasing the risk</strong> – It is important to educate patients regarding the importance of modifying risk factors for deep vein thrombosis (DVT)/PE, including obesity, cigarette smoking, and hypertension. It is also important to educate patients about venous thromboembolic disease so that they can seek medical evaluation promptly if they develop signs and symptoms concerning for DVT/PE. For patients with a family history of clots, we initiate a workup prior to initiating <a class="drug drug_general" data-topicid="9972" href="/d/drug information/9972.html" rel="external">tamoxifen</a>, in order to exclude known genetic causes of hypercoagulability. If a genetic cause of hypercoagulability is found, we do not use tamoxifen. Additionally, for those with a personal history of DVT, we typically avoid tamoxifen. </p><p></p><p class="bulletIndent1">The data suggest that women receiving <a class="drug drug_general" data-topicid="9972" href="/d/drug information/9972.html" rel="external">tamoxifen</a> should discontinue use for several days to weeks prior to prolonged immobilization from anticipated surgery or travel, dependent upon the risks related to both the immobilization itself and patient-related factors [<a href="#rid33">33</a>]. Pharmacokinetics studies suggest that &gt;90 percent of tamoxifen is cleared from plasma within three weeks; meanwhile, peak plasma concentration is reached within two weeks of restarting tamoxifen. Algorithms that account for patient age and duration of immobilization have been published to offer guidance [<a href="#rid33">33</a>].</p><p></p><p class="headingAnchor" id="H5"><span class="h2">Uterine bleeding, hyperplasia, and cancer</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9972" href="/d/drug information/9972.html" rel="external">Tamoxifen</a> has been associated with abnormal uterine bleeding as well as an increased risk of both endometrial cancer and uterine sarcoma. These risks, and their management, are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/14204.html" rel="external">"Abnormal uterine bleeding and uterine pathology in patients on tamoxifen therapy"</a>.)</p><p class="headingAnchor" id="H7454824"><span class="h2">Other tumors</span><span class="headingEndMark"> — </span>An increased risk of nonuterine cancers has not been previously reported in women receiving <a class="drug drug_general" data-topicid="9972" href="/d/drug information/9972.html" rel="external">tamoxifen</a>. However, a modest but significantly increased RR of gastrointestinal tumors (RR 1.31, 95% CI 1.01-1.69) was suggested in a meta-analysis of 16 randomized controlled trials comparing a tamoxifen-containing treatment arm with a similar control arm, in which the incidence of gastrointestinal tumors was reported [<a href="#rid8">8</a>]. Most of this increased risk was derived from three individual Scandinavian trials; the majority of trials and the single largest study (NSABP P-1) did not report significant risk increases.</p><p>Although data are limited, <a class="drug drug_general" data-topicid="9972" href="/d/drug information/9972.html" rel="external">tamoxifen</a> may <strong>reduce</strong> the risk of ovarian cancer. This was illustrated in a retrospective study of 152 breast cancer patients undergoing oophorectomy, 44 of whom were receiving tamoxifen; nine had previously received tamoxifen, and 99 had never received tamoxifen [<a href="#rid34">34</a>]. There was no difference in the frequency of benign ovarian tumors or functional ovarian cysts based upon tamoxifen exposure. However, tamoxifen-treated women were less likely to have ovarian cancer (0 of 53 versus 10 of 99 patients in the tamoxifen and non-tamoxifen groups, respectively). Further studies are required to better define the effect of tamoxifen on ovarian cancer risk.</p><p class="headingAnchor" id="H10"><span class="h2">Eye problems</span><span class="headingEndMark"> — </span>Use of <a class="drug drug_general" data-topicid="9972" href="/d/drug information/9972.html" rel="external">tamoxifen</a> has been associated with an increased risk of cataracts (3.7 percent), and less commonly with reversible corneal pigmentation, and irreversible retinal deposits that have been associated with macular edema and vision loss.</p><p>Although these side effects are uncommon, ocular examination is recommended for any new visual symptoms. (See  <a class="medical medical_review" href="/d/html/96203.html" rel="external">"Ocular side effects of systemically administered chemotherapy", section on 'Tamoxifen and toremifene'</a>.)</p><p class="headingAnchor" id="H773516424"><span class="h2">Fatty liver disease</span><span class="headingEndMark"> — </span>Based on imaging studies, use of <a class="drug drug_general" data-topicid="9972" href="/d/drug information/9972.html" rel="external">tamoxifen</a> has been associated with fatty liver disease in over one-third of patients [<a href="#rid35">35</a>], despite a favorable effect on cholesterol levels. Despite this high frequency, clinically significant steatohepatitis is uncommon. As such, in the absence of other indications, we do not typically monitor liver function tests or imaging for those on tamoxifen.</p><p>If fatty liver disease is detected incidentally, we typically continue <a class="drug drug_general" data-topicid="9972" href="/d/drug information/9972.html" rel="external">tamoxifen</a>, unless liver function tests are elevated to twice the upper limit of normal (in such cases, we hold tamoxifen and refer to a hepatologist for further evaluation). (See  <a class="medical medical_review" href="/d/html/3625.html" rel="external">"Epidemiology, clinical features, and diagnosis of nonalcoholic fatty liver disease in adults"</a> and  <a class="medical medical_review" href="/d/html/3600.html" rel="external">"Management of nonalcoholic fatty liver disease in adults"</a>.)</p><p>Resumption of <a class="drug drug_general" data-topicid="9972" href="/d/drug information/9972.html" rel="external">tamoxifen</a> depends on the baseline risk of recurrence, how long tamoxifen has been administered, contraindications to AIs (which are an alternative in postmenopausal women), and degree of liver injury.</p><p>In a propensity score-matched cohort study of 328 women receiving either <a class="drug drug_general" data-topicid="9972" href="/d/drug information/9972.html" rel="external">tamoxifen</a> or an AI, incidence of fatty liver disease was higher in the tamoxifen group than in the AI group (128.7 versus 81.1 per 1000 person-years, or 37 versus 25 percent of patients), particularly within the first two years of therapy [<a href="#rid35">35</a>]. Risk factors for fatty liver disease included high baseline body mass index and triglycerides and low high-density lipoprotein cholesterol.</p><p class="headingAnchor" id="H2155104883"><span class="h2">Does tamoxifen affect the risk of arterial thromboembolism?</span></p><p class="headingAnchor" id="H569617300"><span class="h3">Stroke</span><span class="headingEndMark"> — </span>There are trials suggesting a modest increase in stroke risk with <a class="drug drug_general" data-topicid="9972" href="/d/drug information/9972.html" rel="external">tamoxifen</a>, but overall these data are conflicting. The possibility that tamoxifen may be associated with an increased incidence of arterial thromboembolism (ie, stroke) was raised in two NSABP randomized trials: P-1 (the breast cancer prevention trial) and NSABP B-24, a trial of tamoxifen for intraductal breast cancer. However, the available data are conflicting, and any increased risk of stroke may be counterbalanced by favorable effects on ischemic heart disease.</p><p>This was shown in the most recent overview analysis of randomized trials of adjuvant <a class="drug drug_general" data-topicid="9972" href="/d/drug information/9972.html" rel="external">tamoxifen</a> from the Early Breast Cancer Trialists' Collaborative Group (EBCTCG) [<a href="#rid28">28</a>]. The nonsignificant excess of stroke deaths (three extra per 1000 women during the first 15 years) in women treated with tamoxifen was exactly balanced by a nonsignificant reduction in cardiac deaths (three fewer per 1000 women during the first 15 years) [<a href="#rid28">28</a>]. Thus, there was little net effect of tamoxifen on overall vascular mortality.</p><p class="headingAnchor" id="H815467829"><span class="h3">Coronary heart disease</span><span class="headingEndMark"> — </span>A lipid-lowering effect has been observed with <a class="drug drug_general" data-topicid="9972" href="/d/drug information/9972.html" rel="external">tamoxifen</a> [<a href="#rid36">36</a>], and several trials have noted beneficial effects from tamoxifen on CHD. However, the data are not consistent.</p><p>In a meta-analysis including 19 randomized trials, <a class="drug drug_general" data-topicid="9972" href="/d/drug information/9972.html" rel="external">tamoxifen</a> was associated with a 33 percent decreased risk of cardiovascular events compared with placebo or no treatment (RR 0.67, 95% CI 0.45-0.98) [<a href="#rid37">37</a>]. The results from extended adjuvant randomized controlled trials comparing tamoxifen with placebo showed a trend towards improved cardiovascular outcomes that did not reach statistical significance (RR 0.91, 95% CI 0.77-1.07).</p><p>By contrast, other data suggest that the use of <a class="drug drug_general" data-topicid="9972" href="/d/drug information/9972.html" rel="external">tamoxifen</a> is not associated with a beneficial cardiovascular effect:</p><p class="bulletIndent1"><span class="glyph">●</span>The NSABP P-1 trial (not included in the meta-analysis above) prospectively evaluated the occurrence of cardiovascular events [<a href="#rid38">38</a>]. Cardiovascular follow-up was available for 13,194 women, 1048 of whom had prior CHD. The rate of cardiovascular events (fatal myocardial infarction [MI], Q-wave MI, non-Q-wave MI, unstable angina, or severe angina requiring revascularization) was not significantly different in women assigned to <a class="drug drug_general" data-topicid="9972" href="/d/drug information/9972.html" rel="external">tamoxifen</a> compared with those receiving placebo, independent of pre-existing CHD. It has been suggested that the large proportion of younger women enrolled on this trial may have obscured the benefit of tamoxifen in terms of cardiovascular disease outcomes [<a href="#rid39">39</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A similar conclusion was reached in a case-control study of 11,045 women enrolled in a single health maintenance organization who developed breast cancer over a 20-year period, 134 of whom had a subsequent MI [<a href="#rid40">40</a>]. Compared with 262 control women who were MI free and matched for year of birth and breast cancer diagnosis, the use of <a class="drug drug_general" data-topicid="9972" href="/d/drug information/9972.html" rel="external">tamoxifen</a> was not associated with a lower risk of MI.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>As noted above, in the most recent overview analysis of randomized trials of adjuvant <a class="drug drug_general" data-topicid="9972" href="/d/drug information/9972.html" rel="external">tamoxifen</a> from the EBCTCG, there was a statistically nonsignificant reduction in cardiac deaths (three fewer per 1000 women during the first 15 years) in women treated with tamoxifen that was counterbalanced by a nonsignificant excess of stroke deaths (three extra per 1000 women) [<a href="#rid28">28</a>].</p><p></p><p>On balance, the available data support the view that in postmenopausal women both with and without CHD, the use of <a class="drug drug_general" data-topicid="9972" href="/d/drug information/9972.html" rel="external">tamoxifen</a> may result in a modest cardiovascular benefit.</p><p class="headingAnchor" id="H2290549779"><span class="h1">AROMATASE INHIBITORS</span><span class="headingEndMark"> — </span>Compared with <a class="drug drug_general" data-topicid="9972" href="/d/drug information/9972.html" rel="external">tamoxifen</a>, the AIs are associated with a higher risk of osteoporosis, fractures, cardiovascular disease, diabetes, and hypercholesterolemia [<a href="#rid37">37,41-44</a>]. By contrast, they are associated with a lower risk of venous thrombosis and endometrial cancer [<a href="#rid42">42</a>], and a lower risk of fatty liver disease [<a href="#rid35">35</a>].</p><p>While AIs are generally well tolerated, side effects may limit adherence in a number of women [<a href="#rid24">24</a>]. In the short term, some studies have suggested that the side effects associated with AIs are not detrimental to quality of life [<a href="#rid45">45,46</a>]. However, in one trial of adjuvant AIs, up to one-third of women may not complete an assigned five-year course of treatment [<a href="#rid46">46</a>]. Furthermore, the long-term effects of AIs (eg, bone loss) have not been fully characterized at this time. While data are available regarding the long-term risks of <a class="drug drug_general" data-topicid="9972" href="/d/drug information/9972.html" rel="external">tamoxifen</a>, and in particular that the risk persists for the duration of treatment but not afterwards [<a href="#rid30">30</a>], such data are limited for aromatase inhibition. Long-term risks of premature menopause, including osteoporosis and cardiovascular risk, which have been observed in noncancer patients, may apply to these patients as well. (See  <a class="medical medical_review" href="/d/html/2062.html" rel="external">"Evaluation and management of aromatase inhibitor-induced bone loss"</a> and  <a class="medical medical_review" href="/d/html/754.html" rel="external">"Overview of long-term complications of therapy in breast cancer survivors and patterns of relapse", section on 'Long-term adverse effects of primary therapy'</a> and  <a class="medical medical_review" href="/d/html/14198.html" rel="external">"Elective oophorectomy or ovarian conservation at the time of hysterectomy", section on 'Long-term health risks'</a>.)</p><p class="headingAnchor" id="H1368727316"><span class="h2">Musculoskeletal pains and stiffness</span><span class="headingEndMark"> — </span>AIs are associated with musculoskeletal side effects including carpal tunnel syndrome as well as a constellation of symptoms including arthralgia, joint stiffness, and/or bone pain, which have been described as the AI-associated musculoskeletal syndrome (AIMSS) [<a href="#rid47">47-51</a>]. These symptoms may be severe in almost one-third of patients [<a href="#rid49">49</a>], and may be responsible for treatment discontinuation in 10 to 20 percent of patients [<a href="#rid48">48-51</a>]. No interventions have yet been identified that prevent development of AIMSS. Recognizing that there are few studies to inform the approach for patients with AIMSS, we suggest the following strategies, typically sequentially, although depending on patient preferences and severity of symptoms, this might not always be the case:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Exercise and NSAIDs</strong> – The initial strategy for managing AIMSS includes exercise and nonsteroidal anti-inflammatory drugs (NSAIDs). In the HOPE trial, 121 physically inactive postmenopausal women with AI-associated arthralgias were randomly assigned to an exercise regimen or to usual care [<a href="#rid52">52</a>]. The exercise regimen consisted of twice-weekly supervised resistance and strength training plus moderate aerobic exercise for 150 minutes per week. Patients undergoing the exercise regimen had reduction in their worst pain score (20 versus 1 percent average score reduction, respectively) and pain severity (21 versus 0 percent reduction) compared with usual care. They also experienced more weight loss and improvement in their exercise capacity. In addition, a dose-response relationship between exercise and symptom severity was identified. Compared with women who attended fewer than 80 percent of the exercise sessions, those who attended 80 percent or more experienced a greater reduction in their worst pain score (25 versus 14 percent, respectively).</p><p></p><p class="bulletIndent1">Beyond exercise, the primary treatment for AIMSS often begins with the administration of NSAIDs because these anti-inflammatory agents are a mainstay of treatment for pain. (See  <a class="medical medical_review" href="/d/html/126633.html" rel="external">"Pharmacologic management of chronic non-cancer pain in adults", section on 'Nonsteroidal antiinflammatory drugs'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Temporary discontinuation of AI, followed by initiation of a different AI</strong> – For women in whom conservative measures including exercise and NSAIDs have been unsuccessful, we discontinue treatment for two to eight weeks and then begin a different AI. In one prospective study, almost 40 percent of patients were able to continue on the alternate AI [<a href="#rid53">53</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Duloxetine</strong> – <a class="drug drug_general" data-topicid="8484" href="/d/drug information/8484.html" rel="external">Duloxetine</a> is an appropriate option for those preferring pharmacologic treatment. In the SWOG S1202 trial, among 299 patients with stage I to III breast cancer who developed AIMSS, those randomized to duloxetine (30 mg daily for one week, then 60 mg daily for 11 weeks, then 30 mg daily for one week) experienced improvement in joint pain through the 12 weeks of treatment relative to placebo [<a href="#rid54">54</a>]. After six weeks, 68 percent of patients treated with duloxetine had experienced at least a two-point improvement in pain, compared with 49 percent treated with placebo. However, 11 weeks after stopping treatment, average pain levels between the groups were similar. Duloxetine was relatively well tolerated; the most common adverse events were grade 1 or 2 fatigue (32 percent), xerostomia (24 percent), nausea (30 percent), and headache (21 percent). Grade 3 or 4 toxicities affected 8.7 percent of patients, with the most common ones being insomnia (2.9 percent) and extremity pain (1.4 percent).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Acupuncture</strong> – Acupuncture offers a nonpharmacologic method of treating AIMSS. In a randomized trial of 226 patients with joint pain on AIs randomly assigned to 12 weeks of acupuncture, sham acupuncture, or waitlist control, those receiving acupuncture experienced a 1 point improvement in 52 week mean pain score on a scale ranging between 0 and 10, over the other groups [<a href="#rid55">55,56</a>]. Although the clinical significance of this small numerical improvement is unclear, some patients may desire a trial of this complementary form of therapy, particularly given its avoidance of systemic side effects.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Switch to </strong><strong>tamoxifen</strong><strong>, for those who are unable or unwilling to continue treatment with an AI. </strong>(See  <a class="medical medical_review" href="/d/html/749.html" rel="external">"Adjuvant endocrine and targeted therapy for postmenopausal women with hormone receptor-positive breast cancer", section on 'Tamoxifen as alternative option'</a>.)</p><p></p><p>Understanding the etiology of AIMSS is complicated because rheumatologic symptoms are present in a significant number of women before they initiate AI therapy. In one study, up to one-half of women who developed AIMSS had a pre-existing musculoskeletal disorder (eg, degenerative joint disease or morning stiffness) [<a href="#rid51">51</a>]. Risk factors for AIMSS have not been fully characterized, but the decrease in estrogen levels with aromatase inhibition may play a role [<a href="#rid50">50,51,57,58</a>].</p><p class="headingAnchor" id="H1345744539"><span class="h2">Osteopenia/osteoporosis</span><span class="headingEndMark"> — </span>AIs inhibit aromatase, the product of the <em>CYP19</em> gene, a member of the cytochrome P450 superfamily; this enzyme is responsible for the peripheral conversion of androgens to estrogens [<a href="#rid59">59,60</a>]. Treatment with AIs, therefore, results in bone loss due to estrogen deficiency [<a href="#rid61">61</a>]. These risks and their management are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/2062.html" rel="external">"Evaluation and management of aromatase inhibitor-induced bone loss"</a>.)</p><p>By contrast, <a class="drug drug_general" data-topicid="9972" href="/d/drug information/9972.html" rel="external">tamoxifen</a> and <a class="drug drug_general" data-topicid="9593" href="/d/drug information/9593.html" rel="external">raloxifene</a> improve bone mineral density in postmenopausal women, as discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/2068.html" rel="external">"Selective estrogen receptor modulators for prevention and treatment of osteoporosis"</a>.)</p><p class="headingAnchor" id="H3962669888"><span class="h2">Ovarian reactivation in pre-/perimenopausal women</span><span class="headingEndMark"> — </span>When premenopausal women are treated with chemotherapy, they can develop amenorrhea or biochemically confirmed ovarian failure that can be temporary or permanent. There is concern that their ovaries may resume estrogen production, thereby making AI therapy ineffective in reducing breast cancer risk. This issue is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/120706.html" rel="external">"Adjuvant endocrine therapy for premenopausal women with hormone receptor-positive breast cancer", section on 'Risk of ovarian function reactivation on an AI'</a>.)</p><p class="headingAnchor" id="H3842180471"><span class="h2">Do AIs increase risk of cardiovascular disease?</span><span class="headingEndMark"> — </span>Some randomized controlled trials have associated AIs with an increased risk of cardiovascular outcomes, but studies on the topic have generated conflicting results [<a href="#rid37">37,44,62</a>]. It is likely that AIs are associated with an increased risk of cardiovascular disease relative to <a class="drug drug_general" data-topicid="9972" href="/d/drug information/9972.html" rel="external">tamoxifen</a>, but have a similar risk relative to placebo.</p><p>For example, in a meta-analysis including 19 randomized trials with over 62,000 patients, AIs were associated with a 19 percent increased risk of cardiovascular events compared with <a class="drug drug_general" data-topicid="9972" href="/d/drug information/9972.html" rel="external">tamoxifen</a> (relative risk [RR] 1.19, 95% CI 1.07-1.34) [<a href="#rid37">37</a>]. However, AIs were not associated with an increased risk compared with placebo in the extended-adjuvant setting (RR 1.01, 95% CI 0.85-1.20).</p><p>In a population-based cohort study of 17,922 women with breast cancer, the use of AIs was associated with increased risks of heart failure and cardiovascular mortality and trends toward increased risks of myocardial infarction and ischemic stroke compared with the use of <a class="drug drug_general" data-topicid="9972" href="/d/drug information/9972.html" rel="external">tamoxifen</a> [<a href="#rid63">63</a>].</p><p class="headingAnchor" id="H869263182"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/121144.html" rel="external">"Society guideline links: Uterine cancer"</a>.)</p><p class="headingAnchor" id="H7454115"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Introduction</strong> – <a class="drug drug_general" data-topicid="9972" href="/d/drug information/9972.html" rel="external">Tamoxifen</a> has antiestrogenic activity in breast tissue, reducing epithelial cell proliferation. However, it modulates estrogen receptor (ER) metabolism in a tissue-specific manner, acting as either an ER agonist or antagonist depending on the tissue. The aromatase inhibitors (AIs; <a class="drug drug_general" data-topicid="10064" href="/d/drug information/10064.html" rel="external">letrozole</a>, <a class="drug drug_general" data-topicid="8780" href="/d/drug information/8780.html" rel="external">anastrozole</a>, and <a class="drug drug_general" data-topicid="8920" href="/d/drug information/8920.html" rel="external">exemestane</a>) do not have tissue-specific effects because they suppress plasma estrogen levels globally, by inhibition of the enzyme aromatase. These differences lead to differences in side effects. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Side effects common to both </strong><a class="drug drug_general" data-topicid="9972" href="/d/drug information/9972.html" rel="external">tamoxifen</a><strong> and AIs</strong> – Hot flashes and sexual dysfunction are among the most common and bothersome side effects of tamoxifen and AIs. Treatment typically includes nonhormonal strategies and is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/7390.html" rel="external">"Menopausal hot flashes", section on 'Women with breast cancer'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Side effects specific to </strong><a class="drug drug_general" data-topicid="9972" href="/d/drug information/9972.html" rel="external">tamoxifen</a></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The relative risks of pulmonary embolism and deep vein thrombosis are increased two- to threefold in older women receiving <a class="drug drug_general" data-topicid="9972" href="/d/drug information/9972.html" rel="external">tamoxifen</a> relative to those not taking it; the risk is higher in women who have inherited a Factor V Leiden mutation. Women receiving tamoxifen should discontinue use for several days prior to prolonged immobilization from anticipated surgery or travel. (See <a class="local">'Venous thromboembolism'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9972" href="/d/drug information/9972.html" rel="external">Tamoxifen</a> has been associated with an increased risk of endometrial cancer, as discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/14204.html" rel="external">"Abnormal uterine bleeding and uterine pathology in patients on tamoxifen therapy"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Further studies are required to better define the effect of <a class="drug drug_general" data-topicid="9972" href="/d/drug information/9972.html" rel="external">tamoxifen</a> on risk of other cancers, including gastrointestinal and ovarian cancer. (See <a class="local">'Other tumors'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Some trials suggest a modest increase in stroke risk with <a class="drug drug_general" data-topicid="9972" href="/d/drug information/9972.html" rel="external">tamoxifen</a>, but overall these data are conflicting. Any increased risk of stroke may be counterbalanced by favorable effects on ischemic heart disease. (See <a class="local">'Does tamoxifen affect the risk of arterial thromboembolism?'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Side effects specific to AIs</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Compared with <a class="drug drug_general" data-topicid="9972" href="/d/drug information/9972.html" rel="external">tamoxifen</a>, the AIs are associated with a higher risk of osteoporosis, fractures, cardiovascular disease, and hypercholesterolemia. By contrast, they are associated with a lower risk of venous thrombosis and endometrial cancer, and a lower risk of fatty liver disease. (See <a class="local">'Aromatase inhibitors'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>AIs are associated with musculoskeletal side effects including carpal tunnel syndrome as well as a constellation of symptoms including arthralgia, joint stiffness, and/or bone pain, which have been described as the<strong> </strong>AI-associated musculoskeletal syndrome. (See <a class="local">'Musculoskeletal pains and stiffness'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Initial treatment typically consists of conservative measures, including exercise and nonsteroidal anti-inflammatory drugs. A brief trial off treatment (typically two to eight weeks) and subsequent resumption of a different AI may be effective.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For patients with persistent symptoms, we suggest <a class="drug drug_general" data-topicid="8484" href="/d/drug information/8484.html" rel="external">duloxetine</a> (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>). Acupuncture is a reasonable nonpharmacologic alternative or adjunctive treatment.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For those in whom the above strategies have been ineffective, a switch to <a class="drug drug_general" data-topicid="9972" href="/d/drug information/9972.html" rel="external">tamoxifen</a> may be appropriate.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Treatment with AIs results in bone loss due to estrogen deficiency. These risks and their management are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/2062.html" rel="external">"Evaluation and management of aromatase inhibitor-induced bone loss"</a>.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Cosman F, Lindsay R. Selective estrogen receptor modulators: clinical spectrum. Endocr Rev 1999; 20:418.</a></li><li><a class="nounderline abstract_t">Riggs BL, Hartmann LC. Selective estrogen-receptor modulators -- mechanisms of action and application to clinical practice. N Engl J Med 2003; 348:618.</a></li><li><a class="nounderline abstract_t">Fisher B, Costantino JP, Redmond CK, et al. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst 1994; 86:527.</a></li><li><a class="nounderline abstract_t">Chalas E, Costantino JP, Wickerham DL, et al. Benign gynecologic conditions among participants in the Breast Cancer Prevention Trial. Am J Obstet Gynecol 2005; 192:1230.</a></li><li><a class="nounderline abstract_t">Kedar RP, Bourne TH, Powles TJ, et al. Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomised breast cancer prevention trial. Lancet 1994; 343:1318.</a></li><li><a class="nounderline abstract_t">Lahti E, Blanco G, Kauppila A, et al. Endometrial changes in postmenopausal breast cancer patients receiving tamoxifen. Obstet Gynecol 1993; 81:660.</a></li><li><a class="nounderline abstract_t">Osborne CK. Tamoxifen in the treatment of breast cancer. N Engl J Med 1998; 339:1609.</a></li><li><a class="nounderline abstract_t">Braithwaite RS, Chlebowski RT, Lau J, et al. Meta-analysis of vascular and neoplastic events associated with tamoxifen. J Gen Intern Med 2003; 18:937.</a></li><li><a class="nounderline abstract_t">Stearns V, Ullmer L, López JF, et al. Hot flushes. Lancet 2002; 360:1851.</a></li><li><a class="nounderline abstract_t">Day R, National Surgical Adjuvant Breast and Bowel Projet P-1 study (NSABP-1). Quality of life and tamoxifen in a breast cancer prevention trial: a summary of findings from the NSABP P-1 study. National Surgical Adjuvant Breast and Bowel Project. Ann N Y Acad Sci 2001; 949:143.</a></li><li><a class="nounderline abstract_t">Jin Y, Hayes DF, Li L, et al. Estrogen receptor genotypes influence hot flash prevalence and composite score before and after tamoxifen therapy. J Clin Oncol 2008; 26:5849.</a></li><li><a class="nounderline abstract_t">Crandall C, Petersen L, Ganz PA, Greendale GA. Association of breast cancer and its therapy with menopause-related symptoms. Menopause 2004; 11:519.</a></li><li><a class="nounderline abstract_t">Biglia N, Cozzarella M, Cacciari F, et al. Menopause after breast cancer: a survey on breast cancer survivors. Maturitas 2003; 45:29.</a></li><li><a class="nounderline abstract_t">Goetz MP, Rae JM, Suman VJ, et al. Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol 2005; 23:9312.</a></li><li><a class="nounderline abstract_t">Bonanni B, Macis D, Maisonneuve P, et al. Polymorphism in the CYP2D6 tamoxifen-metabolizing gene influences clinical effect but not hot flashes: data from the Italian Tamoxifen Trial. J Clin Oncol 2006; 24:3708.</a></li><li><a class="nounderline abstract_t">Johansson H, Gray KP, Pagani O, et al. Impact of CYP19A1 and ESR1 variants on early-onset side effects during combined endocrine therapy in the TEXT trial. Breast Cancer Res 2016; 18:110.</a></li><li><a class="nounderline abstract_t">Otte JL, Flockhart D, Hayes D, et al. Comparison of subjective and objective hot flash measures over time among breast cancer survivors initiating aromatase inhibitor therapy. Menopause 2009; 16:653.</a></li><li><a class="nounderline abstract_t">Fallowfield L, Cella D, Cuzick J, et al. Quality of life of postmenopausal women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Adjuvant Breast Cancer Trial. J Clin Oncol 2004; 22:4261.</a></li><li><a class="nounderline abstract_t">Fallowfield LJ, Kilburn LS, Langridge C, et al. Long-term assessment of quality of life in the Intergroup Exemestane Study: 5 years post-randomisation. Br J Cancer 2012; 106:1062.</a></li><li><a class="nounderline abstract_t">Bernhard J, Luo W, Ribi K, et al. Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials. Lancet Oncol 2015; 16:848.</a></li><li><a class="nounderline abstract_t">Francis PA, Pagani O, Fleming GF, et al. Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer. N Engl J Med 2018; 379:122.</a></li><li><a class="nounderline abstract_t">Boele FW, Schilder CM, de Roode ML, et al. Cognitive functioning during long-term tamoxifen treatment in postmenopausal women with breast cancer. Menopause 2015; 22:17.</a></li><li><a class="nounderline abstract_t">Ganz PA, Petersen L, Bower JE, Crespi CM. Impact of Adjuvant Endocrine Therapy on Quality of Life and Symptoms: Observational Data Over 12 Months From the Mind-Body Study. J Clin Oncol 2016; 34:816.</a></li><li><a class="nounderline abstract_t">Kidwell KM, Harte SE, Hayes DF, et al. Patient-reported symptoms and discontinuation of adjuvant aromatase inhibitor therapy. Cancer 2014; 120:2403.</a></li><li><a class="nounderline abstract_t">Freites-Martinez A, Shapiro J, Chan D, et al. Endocrine Therapy-Induced Alopecia in Patients With Breast Cancer. JAMA Dermatol 2018; 154:670.</a></li><li><a class="nounderline abstract_t">Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998; 90:1371.</a></li><li><a class="nounderline abstract_t">Cuzick J, Forbes J, Edwards R, et al. First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet 2002; 360:817.</a></li><li><a class="nounderline abstract_t">Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Davies C, Godwin J, et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 2011; 378:771.</a></li><li><a class="nounderline abstract_t">Hernandez RK, Sørensen HT, Pedersen L, et al. Tamoxifen treatment and risk of deep venous thrombosis and pulmonary embolism: a Danish population-based cohort study. Cancer 2009; 115:4442.</a></li><li><a class="nounderline abstract_t">Davies C, Pan H, Godwin J, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 2013; 381:805.</a></li><li><a class="nounderline abstract_t">Decensi A, Maisonneuve P, Rotmensz N, et al. Effect of tamoxifen on venous thromboembolic events in a breast cancer prevention trial. Circulation 2005; 111:650.</a></li><li><a class="nounderline abstract_t">Garber JE, Halabi S, Tolaney SM, et al. Factor V Leiden mutation and thromboembolism risk in women receiving adjuvant tamoxifen for breast cancer. J Natl Cancer Inst 2010; 102:942.</a></li><li><a class="nounderline abstract_t">Hussain T, Kneeshaw PJ. Stopping tamoxifen peri-operatively for VTE risk reduction: a proposed management algorithm. Int J Surg 2012; 10:313.</a></li><li><a class="nounderline abstract_t">McGonigle KF, Vasilev SA, Odom-Maryon T, Simpson JF. Ovarian histopathology in breast cancer patients receiving tamoxifen. Gynecol Oncol 1999; 73:402.</a></li><li><a class="nounderline abstract_t">Hong N, Yoon HG, Seo DH, et al. Different patterns in the risk of newly developed fatty liver and lipid changes with tamoxifen versus aromatase inhibitors in postmenopausal women with early breast cancer: A propensity score-matched cohort study. Eur J Cancer 2017; 82:103.</a></li><li><a class="nounderline abstract_t">Grey AB, Stapleton JP, Evans MC, Reid IR. The effect of the anti-estrogen tamoxifen on cardiovascular risk factors in normal postmenopausal women. J Clin Endocrinol Metab 1995; 80:3191.</a></li><li><a class="nounderline abstract_t">Khosrow-Khavar F, Filion KB, Al-Qurashi S, et al. Cardiotoxicity of aromatase inhibitors and tamoxifen in postmenopausal women with breast cancer: a systematic review and meta-analysis of randomized controlled trials. Ann Oncol 2017; 28:487.</a></li><li><a class="nounderline abstract_t">Reis SE, Costantino JP, Wickerham DL, et al. Cardiovascular effects of tamoxifen in women with and without heart disease: breast cancer prevention trial. National Surgical Adjuvant Breast and Bowel Project Breast Cancer Prevention Trial Investigators. J Natl Cancer Inst 2001; 93:16.</a></li><li><a class="nounderline abstract_t">Pritchard KI, Sousa B. Long-term follow-up of women in trials of adjuvant therapy for breast cancer: is it still important? J Clin Oncol 2011; 29:1651.</a></li><li><a class="nounderline abstract_t">Geiger AM, Chen W, Bernstein L. Myocardial infarction risk and tamoxifen therapy for breast cancer. Br J Cancer 2005; 92:1614.</a></li><li><a class="nounderline abstract_t">Hamood R, Hamood H, Merhasin I, Keinan-Boker L. Diabetes After Hormone Therapy in Breast Cancer Survivors: A Case-Cohort Study. J Clin Oncol 2018; 36:2061.</a></li><li><a class="nounderline abstract_t">Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Dowsett M, Forbes JF, et al. Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet 2015; 386:1341.</a></li><li><a class="nounderline abstract_t">Matthews A, Stanway S, Farmer RE, et al. Long term adjuvant endocrine therapy and risk of cardiovascular disease in female breast cancer survivors: systematic review. BMJ 2018; 363:k3845.</a></li><li><a class="nounderline abstract_t">Amir E, Seruga B, Niraula S, et al. Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis. J Natl Cancer Inst 2011; 103:1299.</a></li><li><a class="nounderline abstract_t">Whelan TJ, Goss PE, Ingle JN, et al. Assessment of quality of life in MA.17: a randomized, placebo-controlled trial of letrozole after 5 years of tamoxifen in postmenopausal women. J Clin Oncol 2005; 23:6931.</a></li><li><a class="nounderline abstract_t">Wagner LI, Zhao F, Goss PE, et al. Patient-reported predictors of early treatment discontinuation: treatment-related symptoms and health-related quality of life among postmenopausal women with primary breast cancer randomized to anastrozole or exemestane on NCIC Clinical Trials Group (CCTG) MA.27 (E1Z03). Breast Cancer Res Treat 2018; 169:537.</a></li><li><a class="nounderline abstract_t">Spagnolo F, Sestak I, Howell A, et al. Anastrozole-Induced Carpal Tunnel Syndrome: Results From the International Breast Cancer Intervention Study II Prevention Trial. J Clin Oncol 2016; 34:139.</a></li><li><a class="nounderline abstract_t">Crew KD, Greenlee H, Capodice J, et al. Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer. J Clin Oncol 2007; 25:3877.</a></li><li><a class="nounderline abstract_t">Presant CA, Bosserman L, Young T, et al. Aromatase inhibitor-associated arthralgia and/ or bone pain: frequency and characterization in non-clinical trial patients. Clin Breast Cancer 2007; 7:775.</a></li><li><a class="nounderline abstract_t">Henry NL, Giles JT, Ang D, et al. Prospective characterization of musculoskeletal symptoms in early stage breast cancer patients treated with aromatase inhibitors. Breast Cancer Res Treat 2008; 111:365.</a></li><li><a class="nounderline abstract_t">Morales L, Pans S, Verschueren K, et al. Prospective study to assess short-term intra-articular and tenosynovial changes in the aromatase inhibitor-associated arthralgia syndrome. J Clin Oncol 2008; 26:3147.</a></li><li><a class="nounderline abstract_t">Irwin ML, Cartmel B, Gross CP, et al. Randomized exercise trial of aromatase inhibitor-induced arthralgia in breast cancer survivors. J Clin Oncol 2015; 33:1104.</a></li><li><a class="nounderline abstract_t">Henry NL, Azzouz F, Desta Z, et al. Predictors of aromatase inhibitor discontinuation as a result of treatment-emergent symptoms in early-stage breast cancer. J Clin Oncol 2012; 30:936.</a></li><li><a class="nounderline abstract_t">Henry NL, Unger JM, Schott AF, et al. Randomized, Multicenter, Placebo-Controlled Clinical Trial of Duloxetine Versus Placebo for Aromatase Inhibitor-Associated Arthralgias in Early-Stage Breast Cancer: SWOG S1202. J Clin Oncol 2018; 36:326.</a></li><li><a class="nounderline abstract_t">Hershman DL, Unger JM, Greenlee H, et al. Comparison of Acupuncture vs Sham Acupuncture or Waiting List Control in the Treatment of Aromatase Inhibitor-Related Joint Pain: A Randomized Clinical Trial. JAMA Netw Open 2022; 5:e2241720.</a></li><li><a class="nounderline abstract_t">Hershman DL, Unger JM, Greenlee H, et al. Effect of Acupuncture vs Sham Acupuncture or Waitlist Control on Joint Pain Related to Aromatase Inhibitors Among Women With Early-Stage Breast Cancer: A Randomized Clinical Trial. JAMA 2018; 320:167.</a></li><li><a class="nounderline abstract_t">Sestak I, Cuzick J, Sapunar F, et al. Risk factors for joint symptoms in patients enrolled in the ATAC trial: a retrospective, exploratory analysis. Lancet Oncol 2008; 9:866.</a></li><li><a class="nounderline abstract_t">Mao JJ, Stricker C, Bruner D, et al. Patterns and risk factors associated with aromatase inhibitor-related arthralgia among breast cancer survivors. Cancer 2009; 115:3631.</a></li><li><a class="nounderline abstract_t">Brueggemeier RW. Aromatase, aromatase inhibitors, and breast cancer. Am J Ther 2001; 8:333.</a></li><li><a class="nounderline abstract_t">Smith IE, Dowsett M. Aromatase inhibitors in breast cancer. N Engl J Med 2003; 348:2431.</a></li><li><a class="nounderline abstract_t">Confavreux CB, Fontana A, Guastalla JP, et al. Estrogen-dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole. Prevention with bisphosphonates. Bone 2007; 41:346.</a></li><li><a class="nounderline abstract_t">Cuppone F, Bria E, Verma S, et al. Do adjuvant aromatase inhibitors increase the cardiovascular risk in postmenopausal women with early breast cancer? Meta-analysis of randomized trials. Cancer 2008; 112:260.</a></li><li><a class="nounderline abstract_t">Khosrow-Khavar F, Filion KB, Bouganim N, et al. Aromatase Inhibitors and the Risk of Cardiovascular Outcomes in Women With Breast Cancer: A Population-Based Cohort Study. Circulation 2020; 141:549.</a></li></ol></div><div id="topicVersionRevision">Topic 764 Version 31.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10368777" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Selective estrogen receptor modulators: clinical spectrum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12584371" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Selective estrogen-receptor modulators -- mechanisms of action and application to clinical practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8133536" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15846210" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Benign gynecologic conditions among participants in the Breast Cancer Prevention Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7910323" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomised breast cancer prevention trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8469450" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Endometrial changes in postmenopausal breast cancer patients receiving tamoxifen.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9828250" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Tamoxifen in the treatment of breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14687281" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Meta-analysis of vascular and neoplastic events associated with tamoxifen.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12480376" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Hot flushes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11795346" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Quality of life and tamoxifen in a breast cancer prevention trial: a summary of findings from the NSABP P-1 study. National Surgical Adjuvant Breast and Bowel Project.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19018086" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Estrogen receptor genotypes influence hot flash prevalence and composite score before and after tamoxifen therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15356404" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Association of breast cancer and its therapy with menopause-related symptoms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12753941" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Menopause after breast cancer: a survey on breast cancer survivors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16361630" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16877740" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Polymorphism in the CYP2D6 tamoxifen-metabolizing gene influences clinical effect but not hot flashes: data from the Italian Tamoxifen Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27825388" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Impact of CYP19A1 and ESR1 variants on early-onset side effects during combined endocrine therapy in the TEXT trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19455068" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Comparison of subjective and objective hot flash measures over time among breast cancer survivors initiating aromatase inhibitor therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15514369" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Quality of life of postmenopausal women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Adjuvant Breast Cancer Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22353807" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Long-term assessment of quality of life in the Intergroup Exemestane Study: 5 years post-randomisation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26092816" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29863451" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24977455" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Cognitive functioning during long-term tamoxifen treatment in postmenopausal women with breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26786934" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Impact of Adjuvant Endocrine Therapy on Quality of Life and Symptoms: Observational Data Over 12 Months From the Mind-Body Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24802413" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Patient-reported symptoms and discontinuation of adjuvant aromatase inhibitor therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29641806" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Endocrine Therapy-Induced Alopecia in Patients With Breast Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9747868" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12243915" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21802721" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19569248" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Tamoxifen treatment and risk of deep venous thrombosis and pulmonary embolism: a Danish population-based cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23219286" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15699284" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Effect of tamoxifen on venous thromboembolic events in a breast cancer prevention trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20554945" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Factor V Leiden mutation and thromboembolism risk in women receiving adjuvant tamoxifen for breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22609485" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Stopping tamoxifen peri-operatively for VTE risk reduction: a proposed management algorithm.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10366467" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Ovarian histopathology in breast cancer patients receiving tamoxifen.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28651157" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Different patterns in the risk of newly developed fatty liver and lipid changes with tamoxifen versus aromatase inhibitors in postmenopausal women with early breast cancer: A propensity score-matched cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7593425" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : The effect of the anti-estrogen tamoxifen on cardiovascular risk factors in normal postmenopausal women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27998966" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Cardiotoxicity of aromatase inhibitors and tamoxifen in postmenopausal women with breast cancer: a systematic review and meta-analysis of randomized controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11136837" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Cardiovascular effects of tamoxifen in women with and without heart disease: breast cancer prevention trial. National Surgical Adjuvant Breast and Bowel Project Breast Cancer Prevention Trial Investigators.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21422436" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Long-term follow-up of women in trials of adjuvant therapy for breast cancer: is it still important?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15841078" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Myocardial infarction risk and tamoxifen therapy for breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29688833" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Diabetes After Hormone Therapy in Breast Cancer Survivors: A Case-Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26211827" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30297439" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Long term adjuvant endocrine therapy and risk of cardiovascular disease in female breast cancer survivors: systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21743022" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16157934" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Assessment of quality of life in MA.17: a randomized, placebo-controlled trial of letrozole after 5 years of tamoxifen in postmenopausal women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29455298" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Patient-reported predictors of early treatment discontinuation: treatment-related symptoms and health-related quality of life among postmenopausal women with primary breast cancer randomized to anastrozole or exemestane on NCIC Clinical Trials Group (CCTG) MA.27 (E1Z03).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26598748" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Anastrozole-Induced Carpal Tunnel Syndrome: Results From the International Breast Cancer Intervention Study II Prevention Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17761973" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18021478" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Aromatase inhibitor-associated arthralgia and/ or bone pain: frequency and characterization in non-clinical trial patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17922185" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Prospective characterization of musculoskeletal symptoms in early stage breast cancer patients treated with aromatase inhibitors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18474874" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Prospective study to assess short-term intra-articular and tenosynovial changes in the aromatase inhibitor-associated arthralgia syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25452437" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Randomized exercise trial of aromatase inhibitor-induced arthralgia in breast cancer survivors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22331951" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Predictors of aromatase inhibitor discontinuation as a result of treatment-emergent symptoms in early-stage breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29136387" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Randomized, Multicenter, Placebo-Controlled Clinical Trial of Duloxetine Versus Placebo for Aromatase Inhibitor-Associated Arthralgias in Early-Stage Breast Cancer: SWOG S1202.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36367721" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Comparison of Acupuncture vs Sham Acupuncture or Waiting List Control in the Treatment of Aromatase Inhibitor-Related Joint Pain: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29998338" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Effect of Acupuncture vs Sham Acupuncture or Waitlist Control on Joint Pain Related to Aromatase Inhibitors Among Women With Early-Stage Breast Cancer: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18703382" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Risk factors for joint symptoms in patients enrolled in the ATAC trial: a retrospective, exploratory analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19517460" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Patterns and risk factors associated with aromatase inhibitor-related arthralgia among breast cancer survivors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11550075" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Aromatase, aromatase inhibitors, and breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12802030" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Aromatase inhibitors in breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17618847" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Estrogen-dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole. Prevention with bisphosphonates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18041059" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Do adjuvant aromatase inhibitors increase the cardiovascular risk in postmenopausal women with early breast cancer? Meta-analysis of randomized trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32065766" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Aromatase Inhibitors and the Risk of Cardiovascular Outcomes in Women With Breast Cancer: A Population-Based Cohort Study.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
